Thymosin-alpha 1 Explored as Adjuvant Therapy for High-Risk Colorectal Cancer

Colorectal cancer (CRC) is a significant global health concern, and despite radical resection (surgical removal of the tumor) and subsequent adjuvant chemo/radiotherapy, a substantial 30-40% of patients with high-risk stage II and stage III disease unfortunately experience recurrence and metastasis. This persistent challenge highlights a critical need for more effective post-operative treatments. Thymosin-alpha 1, an immunomodulatory peptide, is believed to enhance immune function and may specifically help promote anti-tumor immunity, offering a potential strategy to address this knowledge gap. This study aims to verify if Thymosin-alpha 1 can safely and effectively reduce the incidence of recurrence and metastasis in these vulnerable patient populations.

As this is a recruiting clinical trial with an estimated completion date of March 31, 2027, specific efficacy and safety data are not yet available. However, the study's primary endpoint is the 3-year disease-free survival (DFS) rate, which will quantify the proportion of patients who remain free of colorectal cancer recurrence or metastasis 3 years after the completion of their adjuvant treatment. Researchers hypothesize that the addition of Thymosin-alpha 1 will lead to a statistically significant improvement in this DFS rate compared to standard care alone. Secondary endpoints will include overall survival, quality of life assessments, and a comprehensive evaluation of adverse events to establish a full safety profile. > The core objective is to ascertain if Thymosin-alpha 1 can significantly reduce colorectal cancer recurrence and metastasis rates over a 3-year period when added to standard adjuvant therapy, thereby improving long-term patient outcomes.